Physician profile
Ward J Odonnell
NPI 1942280300
$2,693.51
in general payments reported to CMS, 2019-2025
24 companies · $215 in 2025
The $215 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $362 · 2020: $211 · 2021: $533 · 2022: $609 · 2023: $402 · 2024: $361 · 2025: $215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $979.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $978.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $470.83 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Glaxosmithkline, LLC. | $372.07 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $224.06 | 2022-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $221.10 | 2019-2024 | |
| Novo Nordisk INC | $218.02 | 2019-2025 | Rybelsus, Ozempic |
| Abbvie INC. | $154.45 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $144.46 | 2020-2022 | |
| Astellas Pharma US INC | $120.12 | 2019-2023 | Veozah |
| Allergan, INC. | $115.29 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $110.63 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $93.51 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $86.72 | 2019-2021 | |
| Amarin Pharma, INC. | $46.37 | 2019 | |
| Idorsia Pharmaceuticals US INC | $44.64 | 2022-2023 | Quviviq |
| Janssen Pharmaceuticals, INC | $41.17 | 2019-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.13 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $40.20 | 2019-2025 | Eliquis |
| Horizon Therapeutics Plc | $39.70 | 2020-2021 | |
| Boston Scientific Corporation | $27.24 | 2025 | Watchman Access System |
| Amgen INC. | $21.54 | 2025 | Repatha, Otezla |
| Averitas Pharma INC. | $20.13 | 2024 | Qutenza |
| Currax Pharmaceuticals LLC | $15.20 | 2025 | Contrave |
| Teva Pharmaceuticals USA, INC. | $13.78 | 2022 | |
| Cequr Corporation | $11.15 | 2024 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ward Odonnell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.